Strides' Net Profit Dives But Regulated Markets Seen Delivering Growth
Strides Shasun has reported third-quarter net profit plunged by 57% but the Indian firm says performance will improve in coming quarters thanks to its regulated market focus, and analysts agree earnings look set to rise.
You may also be interested in...
Strides Shasun Expands Australia Base With Amneal Deal
Indian drug firm Strides Shasun has acquired the Australian unit of Amneal Pharmaceuticals, extending its customer footprint as it sets sights on becoming the leading player in the Australian generics market.
Strides Founder Takes Backseat Role As Profit Surges
Strides Shasun’s founder Arun Kumar has said he will take a backseat strategic role as the Indian pharma firm moves into ‘Version 2’ of its avatar, and will let new leadership drive the company to the ‘next level’ after fourth-quarter earnings nearly tripled.
Strides Says Makeover On Track, Raises EBITDA Guidance
Strides Shasun founder and serial dealmaker Arun Kumar, who’s been bulking up on new acquisitions as he steers the major Indian drug company into a new avatar, says group consolidation is on track and has upped EBITDA guidance after strong second-quarter earnings.